var data={"title":"Balsalazide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Balsalazide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5701?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=balsalazide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Balsalazide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=balsalazide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Balsalazide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139019\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Colazal;</li>\n      <li>Giazo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139034\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        5-Aminosalicylic Acid Derivative;</li>\n      <li>\n        Anti-inflammatory Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139021\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: 2.25 g 3 times daily for 8 to 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Males: 3.3 g twice daily for up to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis, remission maintenance (off-label):</b> 1.5 or 3 g twice daily for 6 to 12 months (Ford 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4005150\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=balsalazide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Balsalazide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Ulcerative colitis:</b> Children and Adolescents 5 to 17 years: Oral: Capsule: 750 mg 3 times daily for up to 8 weeks <b>or</b> 2.25 g 3 times daily for up to 8 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139022\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139023\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Renal toxicity has been observed with other 5-aminosalicylic acid products; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2558398\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139002\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as disodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colazal: 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as disodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Giazo: 1.1 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138989\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3347863\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">May administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule: May be swallowed whole or may be opened and sprinkled on applesauce. Applesauce mixture may be chewed; swallow immediately, do not store mixture for later use. When sprinkled on food, may cause staining of teeth or tongue.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139003\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis</b>: Treatment of mildly- to moderately-active ulcerative colitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Efficacy of Giazo has not been demonstrated in females.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50086274\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Ulcerative colitis, remission maintenance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139041\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Colazal may be confused with Clozaril</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138995\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (children: 15%; adults: 8%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (children: 12% to 13%; adults: &le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Fatigue (children: 4%; adults: &le;2%), insomnia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Vomiting (children: 10%; adults: &le;4%), diarrhea (children: 9%; adults: &le;5%), exacerbation of ulcerative colitis (children: 6%; adults: 1%), nausea (adults: 5%; children: 4%), hematochezia (children: 4%), stomatitis (children: 3%), anorexia (adults: 2%), dyspepsia (adults: 2%), flatulence (adults: &le;2%), abdominal cramps (adults: 1%), constipation (adults: &le;1%), xerostomia (adults: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (adults: 1% to 4%), dysmenorrhea (children: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (adults: &le;4%), musculoskeletal pain (adults: 2%), myalgia (adults: &le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Pharyngitis (children: 6%; adults: 2%), flu-like symptoms (children: 4%; adults: 1%), respiratory infection (adults: &le;4%), cough (children: 3%; adults: 2%), pharyngolaryngeal pain (adults: 4%, children: 3%), rhinitis (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (children: 6%; adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Alopecia, back pain, bowel urgency, bronchopneumonia, cholestatic jaundice, dizziness, dyspnea, edema, erythema nodosum, facial edema, fecal impaction, gastroenteritis, gastroesophageal reflux disease, hepatic cirrhosis, hepatic failure, hepatic injury, hepatic necrosis, hepatotoxicity, hyperbilirubinemia, hypersensitivity reaction, increased blood pressure, increased heart rate, increased liver enzymes, increased serum AST, interstitial nephritis, jaundice, Kawasaki-like syndrome, lethargy, malaise, myocarditis, pain, pancreatitis, pericarditis, pleural effusion, pneumonia (with and without eosinophilia), pruritus, renal failure, skin rash, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139006\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to balsalazide or its metabolites, salicylates, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138993\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Colitis: Symptomatic worsening of ulcerative colitis may occur following initiation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intolerance syndrome: May cause an acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhea; sometimes fever, headache, rash); discontinue if this occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Staining: May cause staining of teeth or tongue if capsule is opened and sprinkled on food. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use caution in patients with hepatic dysfunction; hepatic failure has been observed with other mesalamine (5-aminosalicylic acid) products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pyloric stenosis: Use with caution in patients with pyloric stenosis; prolonged gastric retention may occur and delay release of drug in the colon.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; renal toxicity has been observed with other mesalamine (5-aminosalicylic acid) products. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298812\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138997\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8713&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may decrease the metabolism of Thiopurine Analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138999\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139008\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Mesalamine (5-aminosalicylic acid) is the active metabolite of balsalazide; mesalamine is known to cross the placenta. Refer to the mesalamine monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13316162\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if balsalazide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering balsalazide to nursing women. Mesalamine, 5-aminosalicylic acid, is the active metabolite of balsalazide. Low levels of mesalamine enter breast milk; refer to the mesalamine monograph for additional information. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4005612\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium. Take tablets with or without food. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4005151\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Improvement or worsening of symptoms; renal function (baseline, within first 6 months of initiation, then annually thereafter) (Hanauer 2008); liver function tests (in patients with liver disease)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138992\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Balsalazide is a prodrug, converted by bacterial azoreduction to 5-aminosalicylic acid (mesalamine, active), 4-aminobenzoyl-&beta;-alanine (inert), and their metabolites. 5-aminosalicylic acid may decrease inflammation by blocking the production of arachidonic acid metabolites topically in the colon mucosa.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139005\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Delayed; may require several days to weeks (2 weeks); similar in adults and children  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Very low and variable; in children, reported systemic absorption of 5-ASA (active) lower than adults (C<sub>max</sub>: 67% lower, AUC: 64% lower)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Balsalazide: &ge;99% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Azoreduced in the colon to 5-aminosalicylic acid (active), 4-aminobenzoyl-&beta;-alanine (inert), and N-acetylated metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Primary effect is topical (colonic mucosa); therapeutic effect appears not to be influenced by the systemic half-life of balsalazide (1.9 hours) or its metabolites (5-ASA [9.5 hours], N-Ac-5-ASA [10.4 hours])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Balsalazide: Capsule: 1 to 2 hours; Tablet: 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (65% as 5-aminosalicylic acid, 4-aminobenzoyl-&beta;-alanine, and N-acetylated metabolites); urine (&lt;16% as N-acetylated metabolites); Parent drug: Urine or feces (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139007\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Balsalazide Disodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (280): $447.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Colazal Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (280): $1,873.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Giazo Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.1 g (180): $1,139.45</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539822\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ao Rui Xin (CN);</li>\n      <li>Balzide (IT);</li>\n      <li>Basazyde (TW);</li>\n      <li>Benoquin (AR);</li>\n      <li>Colazal (KR);</li>\n      <li>Colazid (NO, SE);</li>\n      <li>Colazide (AT, AU, CZ, GB, NZ);</li>\n      <li>Colorex (IN);</li>\n      <li>Garian (UY);</li>\n      <li>Intazide (IN);</li>\n      <li>Premid (DK);</li>\n      <li>Sai Lai De (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adhiyaman V, Vaishnavi A, and Froese A, &ldquo;Drug Points: Hypersensitivity Reaction to Balsalazide,&rdquo; <i>BMJ</i>, 2001, 323(7311):489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/11532843/pubmed\" target=\"_blank\" id=\"11532843\">11532843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colazal (balsalazide disodium capsule) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21407188\"></a>Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2011;106(4):601-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/21407188/pubmed\" target=\"_blank\" id=\"21407188\">21407188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giazo (balsalazide disodium tablet) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18670441\"></a>Hanauer SB. Mea Culpa. <i>Nat Clin Pract Gastroenterol Hepatol</i>. 2008;5(8):409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/18670441/pubmed\" target=\"_blank\" id=\"18670441\">18670441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo; <i>Am J Gastroenterol</i>, 2010, 105(3):501-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lennard L, &ldquo;Clinical Implications of Thiopurine Methyltransferase - Optimization of Drug Dosage and Potential Drug Interactions,&rdquo; <i>Ther Drug Monit</i>, 1998, 20(5):527-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/9780130/pubmed\" target=\"_blank\" id=\"9780130\">9780130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robertson E, Austin D, Jamieson N, et al, &ldquo;Balsalazide-Induced Myocarditis,&rdquo; <i>Int J Cardiol</i>, 2008, 130(3):e121-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/balsalazide-drug-information/abstract-text/17889383/pubmed\" target=\"_blank\" id=\"17889383\">17889383</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8713 Version 108.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F139019\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F139034\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F139021\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F4005150\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F139022\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F139023\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F2558398\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F139002\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F138989\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3347863\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F139003\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50086274\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F139041\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F138995\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F139006\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F138993\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298812\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F138997\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F138999\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F139008\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13316162\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F4005612\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4005151\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F138992\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F139005\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F139007\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539822\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8713|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=balsalazide-patient-drug-information\" class=\"drug drug_patient\">Balsalazide: Patient drug information</a></li><li><a href=\"topic.htm?path=balsalazide-pediatric-drug-information\" class=\"drug drug_pediatric\">Balsalazide: Pediatric drug information</a></li></ul></div></div>","javascript":null}